In 2025, Medtronic delivered one of its strongest financial performances in recent years, reporting mid–single-digit revenue growth and a comparable increase in adjusted earnings despite facing potential headwinds from proposed tariffs on medical devices. This robust showing was driven by double-digit growth in its cardiac rhythm and heart failure division, as well as continued strength in its surgical innovations segment. Medtronic’s overall revenue surpassed $35 billion for the first time, marking a significant milestone that underscores the company’s ability to navigate macroeconomic challenges and maintain consistent top-line momentum.

Medtronic achieved a major regulatory milestone with U.S. clearance of its Hugo robotic-assisted surgery system for urologic procedures, paving the way for broader adoption once additional indications are approved. Although Hugo’s initial contribution to revenue is expected to be modest in 2026, the device represents a long-term strategic play in the underpenetrated robotic surgery market, which is projected to grow at over 15% annually through 2030. Concurrently, the company’s Pulse Field Ablation (PFA) franchise continues to gain traction in the electrophysiology market, with procedure volumes increasing by more than 40% year-over-year and contributing over $400 million in revenue during the most recent quarter.

Medtronic’s commitment to returning capital to shareholders remains a cornerstone of its investment thesis. The company increased its dividend for the 48th consecutive year and now yields close to 3%, supported by a modest payout ratio below 50%. Looking ahead, Medtronic is on track to achieve Dividend King status within two years. On the corporate strategy front, management has initiated the divestiture of its diabetes-care business, a unit with lower operating margins, in order to streamline the company’s portfolio and redeploy capital toward higher-growth areas such as minimally invasive therapies and next-generation surgical technologies.